Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,

Novavax has struggled to keep pace with rival vaccine makers Moderna and Pfizer, which reported more than $3 billion in combined sales for their mRNA COVID shots for the third quarter. The company is banking on revenue from its Sanofi deal and vaccines in ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.